Migraines are a silent epidemic in Hong Kong, affecting 1 in 8 people. Yet, it remains widely misunderstood and underdiagnosed. The condition’s hidden burden undermines quality of life, workplace productivity, and the broader economy.

Hong Kong’s rising migraine prevalence, driven by lifestyle and workplace stress, is compounded by systemic challenges such as limited access to and insurance coverage for advanced therapies like CGRP treatments. Current care options are often ineffective or poorly tolerated, leaving patients with suboptimal relief while economic losses mount under a culture of presenteeism and stigma.

Jointly developed by a cross-sector group of clinical, academic, insurance, and HR experts, and funded by Pfizer Hong Kong, this white paper explores the clinical, economic, and social value of advancing migraine care through access to innovative therapies. It draws lessons from global models and advocates for a collaborative, multi-stakeholder approaches to transform migraine management and ensure that no one continues to suffer in silence.

The paper calls for recognising migraine as a critical public health priority and for adopting evidence-based interventions that improve treatment access and support.

Click below to read Hong Kong’s first Migraine White Paper and learn how multi-stakeholder action can turn the tide on migraine care.